RVNC—Just to be clear, SAKURA is the name for the entire phase-3 program of RT002 in glabellar lines, which consists of: two identical randomized, controlled efficacy trials, where patients receive a single treatment; and one open-label safety trial where some patients receive a second treatment and are followed for as long as 84 weeks.
Someone on Twitter asked if there will be an interim analysis in the efficacy trials; the answer is no—it wouldn't make any sense in this kind of trial.
Market Data 
Markets 
AI
